Metal complexes in medicine with a focus on enzyme inhibition
1Department of Chemistry and Open Laboratory of Chemical Biology of the Institute of Molecular Technology for Drug Discovery and Synthesis, The University of Hong Kong, Pokfulam Road, Hong Kong, China. cmche@hku.hk
Abstract:
Since the clinical success of cisplatin and its derivatives, considerable effort has been expended by academics and pharmacological companies to the development of novel metal-based drugs. DNA is believed to be the main target of cisplatin, and there have been extensive studies on the binding between metal complexes and DNA targets. Recently, new light has been shed on the discovery of metal-based drugs that inhibit enzymatic activities or even target proteins directly. This review highlights some exciting results published recently on the development of platinum, gold, and ruthenium complexes as enzyme inhibitors for potential therapeutic applications.
Related Concept Videos
Enzyme Inhibition
Metal-Ligand Bonds
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
Complexation Equilibria: The Chelate Effect
Complexation Equilibria: Factors Influencing Stability of Complexes
EDTA: Chemistry and Properties
The Electron Transport Chain
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...


